Cohance Lifesciences, a pharma CRDMO spanning API+, Pharma CDMO and Speciality Chemicals, reports its second quarter with the central question being whether the sequential recovery management guided after the Q1 trough has actually landed. The print will speak to the pace of margin repair from Q1's 2.2% adjusted EBITDA margin toward the FY27 target of a margin 'closer to previous year', and to the NJ Bio drag that cost Rs. 328 Mn in EBITDA last quarter.
| Results date | November 06, 2026 |
|---|---|
| Quarter | Q2 FY 2026-2027 |
| Previous quarter revenue | Rs. 4,223 Mn |
| Previous quarter PAT | Rs. (452) Mn (reported) |
| Previous quarter EBITDA margin | 2.2% (adjusted) |
| Market cap | Rs. 17,234.1 Cr |
| CMP | Rs. 450.45 |
A board meeting is scheduled on 6 November 2026 to consider the Q2/H1 FY27 results; the trading window is shut till 9 November 2026.
The Q2/H1 FY27 earnings call is scheduled for 6 November 2026 at 6:00 PM IST, having been moved from an earlier 6:30 PM IST slot; results will be released earlier the same day.
The quarter is framed around management's guided path of a Q1 FY27 trough (revenue Rs. 4,223 Mn, -23.1% YoY) with sequential improvement in Q2 and a return to YoY growth from H2 FY27. External demand proxies support a better sequential quarter: India's bulk drugs and intermediates exports accelerated through the window, with August up 8.61% to $440.35mn and September up 14.62% to $509.25mn (September volumes +22.36%), and the latest sector report shows the API sub-segment leading Q2 FY27 with 33.4% median revenue growth.
Company-specific supports include the customized ADC payload scheduled for Q2 FY27 delivery, two recently commercialized molecules delivering six intermediates across Q2-Q3 FY27, and 2 FDF launches slated for Q2 out of around 10 for FY27.
On margins, the Q1 gross-margin hit (71.5%, down 150 bps YoY on freight and KSM escalation) should not deepen on current spot — the China API/KSM index was flat sequentially and ~3% lower YoY, and container rates were stable ($4,374/40-ft on 23 Jul to $4,476 on 10 Sep) — but NJ Bio's Rs. 328 Mn Q1 EBITDA loss remains the bigger consolidated swing factor, with early-stage biotech budgets still squeezed even as large-cap funding recovers.
Management's FY27 anchor of an adjusted EBITDA margin 'closer to previous year' (FY26: 21.0%) implies a steep climb from Q1's 2.2%, and the recovery is H2-weighted by design. Two guidance commitments fall due on this call: quantification of restocking revenue from the Rs. 260 crore destocking pool (promised 'by the end of the second call') and any quantified FY27 revenue-growth guidance, with clarity on the US$1bn-by-2030 aspiration promised by December 2026.
This is also the first call with Chairman & Group CEO Umang Vohra and CFO Abhimanyu Ojha, so any change in guidance framework or capital-allocation language will be worth noting.
Performance vs guidance tracking: Several FY27 commitments fall due on or around this call.
NJ Bio drag and consolidated-vs-standalone gap
USFDA regulatory overhang
Strategic execution under new leadership: First call for Chairman & Group CEO Umang Vohra and CFO Abhimanyu Ojha.
The CFO said it is 'a bit early' to quantify how much of the INR 260 crore would come in, with clarity promised 'by the end of the second call' this year and for FY28. Of the two affected molecules, only one has a restocking order in hand so far, spread over two years.
Management guided to a margin 'closer to previous year margin percentage' for FY27, with margins expected to 'start accelerating from FY28 onwards'. FY26 adjusted EBITDA margin was 21.0% consolidated, versus 2.2% in Q1 FY27.
On the Q1 FY27 call, the CEO called the US$1bn+ revenue target by 2030 'an aspiration and more clarity will be provided by December', acknowledging the company 'might be a bit away from it in the next 3-4 years'. The mid-to-long-term framework also includes mid-30s EBITDA margins and 80%+ CDMO share of revenue by 2030.
No quantified FY27 revenue growth guidance has been provided; it remained outstanding at both the Q4 FY26 and Q1 FY27 calls. Management has guided to a growth year weighted towards H2, with Q1 FY27 the low point and YoY growth from H2 FY27.
Disclaimer: This earnings preview is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.